Based on Table 3, MIA2G has higher sensitivity (91%, 95% CI: 84.8–95.3%) than CA-125 (76.7%, 95% CI: 68.6–83.6%) in identifying early-stage ovarian cancer. This evidence concerns the gene MUC16 and ovarian cancer.